Prostate Cancer
Prostate cancer and novel pharmacological treatment options - what's new for 2022?
February 20, 2023
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
February 20, 2023
Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
February 20, 2023
Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo.
February 17, 2023
Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system.
February 17, 2023
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
February 17, 2023
Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes.
February 16, 2023
Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer.
February 16, 2023
Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer.
February 16, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
February 15, 2023
Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it.
February 15, 2023
Age-stratified potency outcomes of bilateral nerve sparing robotic-assisted radical prostatectomy.
February 15, 2023